Hamlet Pharma announced the appointment of Petter Segelman Lindqvistas new CEO, starting October 1st 2023. The recruitment of Petter Segelman Lindqvist marks a new phase in the development of Hamlet BioPharma's groundbreaking technologies for cancer and infection therapy. Petter Segelman Lindqvist's extensive experience from the global pharmaceutical Industry will increase the emphasis on partnering, commercialization and future market approval.

The board wishes to thank Martin Erixon, who will stay as CEO until Petter Segelman Lindqvist joins the company in the fall of 2023. Petter Segelman Lindqvist, with a background at pharmaceutical companies such as GlaxoSmithKline, Abbott and AbbVie, is currently holding a position as Portfolio Strategy Lead at Sobi (Swedish Orphan Biovitrum AB). He brings significant experience from the Global Strategy and Corporate Development functions, as well as from roles in global commercial operations and product strategy.

Petter Segelman Lindqvist holds an MSc in Economics and Business Administration from the Stockholm School of Economics and EM Lyon, France.